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Abstract
Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer’s disease (AD)
continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms
of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of
advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging
(MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of
SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from
local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging
signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD,
such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for
the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along
with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the
context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with
patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging
techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying
pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with
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more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their
clinical utility.
Keywords: subjective cognitive decline, Alzheimer’s disease, neuroimaging, multimodal MRI, PET
Highlights
 The main imaging features and neuroimaging
advances in individuals with SCD related to AD are
summarized.
 The symptoms of SCD are associated with specific
and distinctive underlying pathological events.
 A preferential vulnerability of AD-signature regions
in individuals with SCD are described.
 The risk factors for dementia due to AD may
interact with SCD and aggregate brain alterations.
Background
Alzheimer’s disease (AD) is one of the most common
causes of dementia, with a dramatically increasing inci-
dence in recent years that is expected to reach 115 million
in 2050 [World Alzheimer Report 2018, www.alz.co.uk].
Currently available treatments are moderately beneficial at
best for the symptomatic stages of AD [1]. Patients with
preclinical AD are defined as cognitively unimpaired indi-
viduals with abnormal AD biomarkers [2]. At this very
early stage, individuals still have sufficiently intact cogni-
tive function that can be harnessed and directed toward
either compensation or restitution of function [3]. More
importantly, evolving biomarker studies enable to identify
individuals with preclinical AD, which provides the best
opportunity for therapeutic success and prevents cognitive
decline before the onset of clinical symptoms.
Subjective cognitive decline (SCD), the first clinical
manifestation in the AD continuum, is self-experienced
decline in cognitive function without evidence of object-
ive cognitive impairment [3–5]. SCD is postulated to
manifest at a relatively late phase of preclinical AD and
is associated with increased risks of AD biomarker ab-
normalities and future cognitive decline and dementia
[2, 4, 6], making it a high-risk condition for the develop-
ment of dementia due to AD. However, knowledge
about the relationship between SCD and AD neuroimag-
ing biomarkers is still controversial. Thus, investigating
populations with SCD is important for understanding
the early pathological mechanisms of preclinical AD and
identifying SCD-related biomarkers, which are crucial
for the early detection of AD with relatively inexpensive
and easy measures.
Although SCD is a heterogeneous concept that can be
induced by many conditions other than AD [4], includ-
ing normal aging, psychiatric conditions (e.g.,
depression), other neurological and medical disorders
(e.g., frontal temporal dementia and dementia with Lewy
bodies), substance abuse and certain medications, we
specifically focus on SCD due to AD, and these other
conditions have been excluded from all studies included
in this review. With the advent of neuroimaging tech-
niques, such as positron emission tomography (PET)
and magnetic resonance imaging (MRI) [7], structural
and functional brain alterations have been detected
in vivo during the asymptomatic stage of AD [8, 9]. An
increasing number of neuroimaging studies have indi-
cated that the symptoms of SCD are associated with spe-
cific and distinctive underlying pathological events, such
as the abnormal deposition of ß-amyloid and tau pro-
teins, gray matter atrophy, disruptions in the white mat-
ter (WM) and deficits in brain function [3, 10, 11]. The
utility of neuroimaging techniques makes it possible to
understand the neuropathological mechanisms under-
lying SCD related to AD and to provide potential patho-
logical and imaging biomarkers for the early detection
and even prediction of AD.
The purpose of this review is to provide a state-of-the-
art and comprehensive summary of the literature regard-
ing advances in neuroimaging findings in individuals
with SCD within the context of AD by including studies
using different imaging modalities. The limitations of
current studies and future directions are also discussed.
Methods
We searched the PubMed and Science Direct databases
for articles describing the neuroimaging changes in indi-
viduals with SCD related to AD published from January
1994 to September 2019. The search terms used were
“((subjective cognitive decline[Title/Abstract]) OR (sub-
jective memory decline[Title/Abstract]) OR (subjective
cognitive complaint[Title/Abstract]) OR (subjective cog-
nitive complaints[Title/Abstract]) OR (subjective mem-
ory impairment[Title/Abstract]) OR (subjective memory
impairments[Title/Abstract]) OR (subjective memory
complaint[Title/Abstract]) OR (subjective memory com-
plaints[Title/Abstract]) OR (cognitive complaints[Title/
Abstract]) OR (subjective cognitive impairment[Title/
Abstract]) OR (subjective cognitive impairments[Title/
Abstract])) AND (Alzheimer’s disease) AND (neuroim-
aging OR PET OR MRI OR EEG OR MEG OR NIRs OR
ASL OR DKI OR DSI OR DTI OR fMRI OR sMRI OR
QSM)”. The studies were included based on the
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following inclusion criteria: (1) studies that described
neuroimaging changes in individuals with SCD related
to AD, (2) participants with SCD exhibited normal per-
formance on standard neuropsychological tests and were
free of other medical or psychiatric causes, and (3) ori-
ginal research published in English with the full-text
available, regardless of the research settings. The follow-
ing types of studies were excluded: (1) case reports, con-
ference abstracts, reviews and study design or protocols,
(2) studies with an interventional/experimental study de-
sign, and (3) studies not related to our topics: i.e., studies
that did not use neuroimaging markers and studies
focused on SCD that was caused by other conditions
(e.g., cerebrovascular disease, epilepsy, Parkinson’s dis-
ease, dementia with Lewy bodies, etc.), studies focused
on MCI or dementia populations, studies focused on
other risk factors for impaired cognitive function (e.g.,
sleep changes, depression, nutritional status, etc.) and
studies focused on other topics not related to our aim.
After detailed evaluations, 114 studies were included and
reviewed. A detailed description of the article selection
process is presented in the flowchart (Fig. 1). We dis-
cussed and summarized the neuroimaging changes re-
lated to SCD in the background of AD in detail
Figure 1 Flowchart of the literature screening process and results. Abbreviations: SCD=subjective cognitive decline; CVD=cerebrovascular disease;
PD=Parkinson’s disease; DLB=dementia with Lewy body; MCI=mild cognitive impairment; AD=Alzheimer’s disease
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according to the different neuroimaging modalities, in-
cluding neuroimaging performed at the molecular, struc-
tural, and functional levels.
Standard terminology and diagnostic criteria
The concept of SCD was first introduced in the early 1980s
by Reisberg and colleagues to define an early stage of AD
and was initially assessed using the Global Deterioration
Scale [12]. In recent years, SCD has received various labels,
including subjective cognitive complaints, subjective mem-
ory complaints, subjective cognitive impairment, subjective
memory impairment, subjective memory decline and others
[4]. Although the impairment has attracted increasing at-
tention since 2005, SCD research has been hampered by
the lack of a common nomenclature, and uniform criteria
for defining SCD are not available. Some studies identified
SCD with a single question such as “Do you feel you can re-
member things as well as you used to?”, while other groups
assessed SCD with structured questionnaires such as the
Mood and Feelings Questionnaire (MFQ) and/or the self-
evaluated Everyday Cognition Scale (E-Cog). In 2014, a
consensus terminology and a conceptual framework for re-
search on SCD related to AD was proposed by the Subject-
ive Cognitive Decline Initiative (SCD-I) [4]. This framework
unified the multiple descriptors into a single term, SCD,
and presented a set of features of SCD due to AD, named
“SCD-plus”, to facilitate the comparison of study findings,
data pooling, meta-analyses, and collaborative multicenter
research. These features include onset within 5 years, age at
onset ≥ 60 years, concerns regarding feelings of worse per-
formance than other individuals of the same age, confirm-
ation of cognitive decline by an informant, possession of
the Apolipoprotein E (ApoE) ɛ4 genotype and the presence
of biomarker evidence for AD. Recently, two additional
SCD plus features were proposed, including consistent
SCD over time and seeking medical help because of SCD
[5]. The framework also supports some flexibility in the
classification of SCD, but researchers are responsible for ex-
plicitly clarifying how they operationalize SCD and why
they chose a particular approach. All these efforts help fur-
ther advance the investigation of SCD related to AD.
Only a few longitudinal studies of people with carefully
phenotyped SCD have investigated the rate of progres-
sion of SCD to dementia due to AD [13, 14]. With clin-
ical advances, the increasing number of memory clinics
will facilitate the enrollment of subjects with SCD and
increase awareness about SCD and the concept of cogni-
tive protection.
Positron emission tomography
β-amyloid deposition
The advent of PET amyloid tracers allows the quantifica-
tion of amyloid deposition in vivo [15–17]. 11C-Pitts-
burgh Compound B (PiB) was the first amyloid PET
ligand with high affinity for amyloid [18]. Additionally,
the development of 18F-labeled ligands (18F-florbetapir,
18F-florbetaben and 18F-flutemetamol) has facilitated
their widespread use due to longer half-lives (~110 min)
[19–21]. A meta-analysis reported a prevalence of amyl-
oid pathology among individuals with SCD of 12%-43%
[22]. According to Perrotin et al. and Snitz et al., sub-
jects with SCD showed a significant increase in amyloid
positivity compared with healthy controls (HCs) [23, 24].
Furthermore, several studies using the amyloid load as a
continuous variable verified the relationship between the
amyloid burden and the severity of SCD [25–29]. How-
ever, some other studies did not report this relationship
[30–33]. Therefore, the correlations between the exist-
ence and severity of SCD with amyloid pathology remain
inconsistent, potentially due to the different research set-
tings and methods for the operationalization of SCD
used among studies.
In clinical patients with dementia due to AD, amyloid
deposition exhibits a diffuse pattern that initiates from
the prefrontal and posterior parietal regions with the
highest vulnerability [34, 35]. Interestingly, a similar pat-
tern of the spatial distribution of amyloid deposition was
also observed in individuals with SCD, which was mainly
distributed in the temporal [24], medial prefrontal, an-
terior and posterior cingulate cortices and the precuneus
[25]. Therefore, consistent with the “amyloid cascade”
hypothesis [36], the increase in amyloid levels in AD-
specific regions might be associated with SCD, poten-
tially more than 10 years prior to the ensuing cognitive
impairment.
Furthermore, several studies have focused on the clin-
ical features of SCD, such as specific involved cognitive
domains, related concerns, and the confirmation of in-
formants, and explored their relationships with the
amyloid burden to increase the predictive power of SCD
to the underlying amyloid pathology. For example,
Amariglio et al. (2012) revealed a significant correlation
between scores of the memory and executive subscales
of SCD with the amyloid burden [29]. As shown in an-
other study, self-reported confusion, but not the total
SCD score, predicted global and regional amyloid depos-
ition in SCD [32]. Moreover, SCD-related worry was also
found to be associated with the cortical amyloid load
[33]. Therefore, the additional features of SCD may en-
hance its association with AD pathology.
Recently, several studies have consistently suggested that
higher amyloid aggregation at baseline indicated a faster
rate of decline in various cognition domains [37, 38] and a
more rapid increase in SCD severity over time [39] in indi-
viduals with SCD. In addition, subjects in the amyloid-
positive group with a greater number of subjective mem-
ory complaints displayed a greater rate of progression to
mild cognitive decline (MCI) [40] and dementia due to
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AD [41]. These investigations provided evidence that SCD
with a high amyloid load may indicate a faster longitudinal
cognitive decline and worse clinical progression.
Notably, amyloid deposition in subjects with SCD is
also affected by other risk factors for dementia due to
AD, such as the ApoE ɛ4 genotype and age. Individuals
with SCD may present higher allelic frequencies of ApoE
ɛ4, and cerebral amyloid levels might be partially pre-
dicted by the ApoE ɛ4 level [42]. In another study of in-
dividuals with SCD from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database, ApoE ɛ4 car-
riers with SCD showed higher levels of amyloid accumu-
lation than noncarriers. However, no hypometabolism or
atrophy was detected [43]. Aging is also associated with
increased cerebral amyloid deposition in cognitively nor-
mal elderly people. A meta-analysis [22] reported an as-
sociation between the occurrence of cerebral amyloid
pathology in cognitively normal individuals and age, in-
creasing from 10% to 44% in individuals between 50 and
90 years of age. Zwan et al. (2016) assessed multiple risk
factors for high amyloid levels, including SCD, the ApoE
genotype, age, and episodic memory [44], to further elu-
cidate the relationship. However, the effects of the inter-
actions among SCD, the ApoE genotype, age and other
potential contributing factors on preclinical AD are
complicated and are not completely understood to date.
Therefore, additional investigations are needed to clarify
the relationship among different risk factors for demen-
tia due to AD.
Tau burden
Pathological tau deposition represents another key bio-
marker of AD [45, 46]. The development of selective tau
tracers, such as the most extensively used tracer 18F-
Flortaucipir [47], allows researchers to investigate re-
gional distribution of tau pathology in the living human
brain [46, 48, 49]. In the preclinical stage, the relation-
ship between the symptoms of SCD and tau burden has
been reported by Swinford and colleagues [50]. They
scanned SCD subjects using 18F-flortaucipir PET and de-
termined that the self-reported memory concern was as-
sociated with frontal tau levels, whereas the informant-
reported concern was related to parietal tau levels. How-
ever, until now, the tau PET studies in individuals with
SCD are currently limited. More evidence is needed to
further elucidate the association between tau and amyl-
oid pathology and their contribution to SCD and clinical
progression.
Cerebral glucose metabolism
18F-Fluorodeoxyglucose (FDG)-PET has been used to
quantify abnormal cerebral glucose metabolism [40, 51, 52].
Hypometabolism in individuals with MCI and dementia
due to AD have been consistently confirmed, primarily in
the posterior parietal and temporal regions [53, 54]. The
hypometabolic profile in AD-related regions has been char-
acterized in subjects with SCD and involves the parietotem-
poral cortex, precuneus, precentral and parahippocampal
gyri [55–57]. However, Scheef et al. (2012) observed in-
creased metabolism in the right medial temporal lobe in
the SCD group compared with HCs, which may suggest
compensatory neuronal activity. Additionally, metabolic
deficits associated with SCD have been observed in high-
risk genetic carriers of ApoE ɛ4 [55].
Moreover, some studies have explored the relationship
between regional glucose metabolism and cognitive per-
formance in subjects with SCD. For example, the metab-
olism in both the left hippocampus and the right
amygdala was positively correlated with verbal logical
memory immediate recall [58]. FDG-PET not only en-
ables the prediction of cognitive function but also may
serve as a prognostic marker for tracking longitudinal
cognitive changes. Scheef and colleagues identified an
association between hypometabolism in the right precu-
neus at baseline and the degree of longitudinal memory
decline [59]. Based on these findings, hypometabolism
may be a potential functional biomarker for the early de-
tection of AD (Table 1).
Structural MRI and diffusion MRI
Gray matter
Both cortical and subcortical atrophy develop as AD
progresses, making its volumetry one of the most well-
established imaging biomarkers of AD [62]. As preferen-
tial target locations of neurofibrillary tangles [45], the
entorhinal cortex and hippocampus display marked atro-
phy in patients with dementia due to AD [63–66].
However, during the SCD stage, neuroimaging find-
ings regarding gray matter changes remain mixed. Some
studies have observed a decreased hippocampal volume
in individuals with SCD both at baseline [59, 67–74] and
during a significant longitudinal decline, with an annual
decrease of 1.9% [75, 76], whereas other studies have not
reported significant changes [77–83]. The heterogeneity
of SCD may be one of the causes of the inconsistent re-
sults, as evidence has suggested that patients with clinic-
ally defined SCD who present with smaller brain
volumes have a higher risk of developing dementia than
community-recruited subjects with SCD [23]. When
combined with genetic risk factors, SCD subjects who
are ApoE ɛ4 carriers showed more severe atrophy in the
left hippocampus [84] and an additive reduction in the
right cortical surface area [85] than noncarriers; this out-
come is consistent with the results from longitudinal
studies [86]. Furthermore, some studies have investi-
gated the volumetric differences in subcortical regions,
including the cholinergic basal forebrain nuclei and the
hippocampal subfield, between individuals with SCD and
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Table 1 Summary of PET studies
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Amariglio et al. (2012)
[29]
E-Cog;
MFQ;
Composite of 7 questions
PiB-PET Cross-
sectional
SCC: n=131(73.5±6.0)
amyloid-: n=97(72.7±5.9)
amyloid+: n=34(75.5±6.9)
SCC score relate to cortical
PiB binding
Amariglio et al. (2018)
[39]
Composite of 7 questions PiB-PET Cross-
sectional
All: n=279(73.4±6.1)
amyloid-: n=209(72.9±6.0)
amyloid+: n=70(70.0±5.7)
Amyloid positivity individuals
have pronounced progression
of SCD
Buckley et al. (2016) [41] MAC-Q scale PiB-PET
18F-florbetapir
PET
18F-flutematamol-
PET
MRI
Cross-
sectional
NC: n=288
amyloid-: n=230(69±5.9)
amyloid+: n=58(72±7.2)
High SMD related to greater
rates of clinical progression,
greater depressive symptom
and smaller left hippocampal
volume
Cacciamani et al. (2017)
[31]
Composite of 15 questions
IQCD
ASC
AD-NOS
18F-florbetapir
PET
MRI
FDG-PET
Cross-
sectional
High awareness:
n=86(76.08±0.36)
Low awareness:
n=19(76.11±0.82)
No relationship between SCD
score and neuroimaging
markers; higher amyloid
burden and lower cortical
metabolism in “high
awareness” group
Chen et al. (2019) [27] Metamemory in Adulthood
questionnaire
18F-florbetapir
PET
MRI
Cross-
sectional
Total: n=85(66.97±15.11)
Negative: n=53(61.25±14.86)
Positive: n=32(76.46±9.96)
Poor memory performance
mediates the relationship
between amyloid and SCD
Hollands et al. (2015) [37] MAC-Q
Composite of 16 questions
PiB-PET Cross-
sectional
Low Aß: n=224(68.37±5.88)
High Aß: n=65(73.46±7.33)
High Aß group show
moderate decline in
learning and working
memory over 18 months.
McCluskey.et al. (2018)
[32]
MAC-Q
1 binary question
18F-florbetaben
PET
Cross-
sectional
All: n=112(69.2, 2.5) Self-reported confusion
predicted higher global
amyloid burden and
regional amyloid in the
prefrontal, posterior
cingulate, precuneus and
the lateral temporal.
Moreno–Grau et al.
(2018) [42]
Cognitive complaints 18F-florbetaben
PET
18F-florbetapir
PET
Cross-
sectional
ADNI_NC: n=182(73.4±6.3)
ADNI_SMC: n=103(72.2±5.6)
ADNI_EMCI: n=303(71.3±7.4)
ADNI_LMCI: n=157(72.2±7.5)
ADNI_AD: n=144(74.4±8.1)
FACEHBI_SCD: n=200(65.8±7.1)
ADNI_NC: n=182(73.4±6.3)
Higher ApoE ɛ4 carrier in
SCD and ApoE ɛ4 dosage
explained 9% and 11%
cerebral amyloid variation.
Perrotin et al. (2017) [23] Composite of 26 questions 18F-florbetapir
PET
MRI
Cross-
sectional
Controls: n=35(65.6±8.6)
SCDcommunity: n=35(70.8±7.5)
SCDclinic:
n=28(67.6±7.7)
Both groups with high
self-reported difficulties
has higher amyloid
deposition
Perrotin et al. (2012) [25] 2 questions PiB-PET
MRI
Cross-
sectional
High PiB uptake: n=11(75.73±
6.05)
Low PiB uptake: n=28(71.89±
5.45)
Correlation between memory
self-reports and regional PiB
uptake in right medial
prefrontal, anterior cingulate,
right precuneus and posterior
cingulate.
Risacher et al. (2015) [43] CCI
E-Cog
18F-florbetapir
PET
FDG-PET
MRI
Cross-
sectional
NC ApoE ɛ4-: n=132(73.7±6.1)
NC ApoE ɛ4+: n=53(71.8±6.4)
SMC ApoE ɛ4-: n=71(72.5±5.7)
SMC ApoE ɛ4+: n=33(70.3±5.2)
EMCI ApoE ɛ4-: n=174(71.6±7.3)
EMCI ApoE ɛ4+: n=131(70.0±7.5)
SMC ApoE ɛ4+ show greater
amyloid deposition than SMC
ApoE ɛ4-
Rodda et al. (2010) [30] Memory complain PiB-PET Cross-
sectional
No presented No difference in amyloid load
between SCI and controls
Rowe et al. (2010) [28] 1 binary question PiB-PET
MRI
HC: n=177(71.6±7.4)
MCI: n=57(75.5±7.5)
AD: n=53(72.6±8.9)
HC nMC: n=81(72.0±7.5)
HC SMC: n=96(71.2±7.4)
SMC related to elevated PiB in
ApoE ɛ4 carriers
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Table 1 Summary of PET studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Snitz et al. (2015) [24, 26] MFQ
CFQ
SCCS
PiB-PET Cross-
sectional
SCD: n=14(68.1±4.0)
NC: n=84(73.6±5.8)
57% of SCD and 31% of NC
were PiB-positive. SCD had
higher PiB retention in frontal
cortex, lateral temporal cortex,
and parietal cortex.
Snitz et al. (2015) [24, 26] MFQ
CFQ
SCCS
PiB-PET Cross-
sectional
Total: n=92(81.2±8.4) MFQ score relate to global PiB
retention
Timmers et al. (2019) [38] Memory clinic consultation
Intact cognition
18F-florbetapir
PET
Cross-
sectional
Total: n=107(64±8) Higher 18F-florbetapir BPND
relates to steeper rate of decline
on memory, attention/executive
and language
Verfaillie et al. (2019) [33] CCI
SCF
Composite of 4 questions
18F-florbetapir
PET
Cross-
sectional
Total: n=106(63.83±7.65) Higher cortical amyloid
deposition relates to
SCD-related worries and
higher memory deficit
awareness but not to SCD
questionnaires
Zwan et al. (2016) [44] MAC-Q
IQCODE-S
PiB-PET
18F-flutematamol
PET
Cross-
sectional
Low amyloid burden: n=
229(71.9±6.5)
High amyloid burden: n=
78(75.0±7.2)
SMC with younger age and
ApoE ɛ4 carriers had higher
amyloid burden.
Swinford et al. (2018) [50] E-Cog 18F-flortaucipir
PET
Cross-
sectional
CN: n=40(76.48±7.211)
SMC: n=11(71.55±5.11)
EMCI: n=31(75.32±7.29)
Memory concern and the
self-perception relate to tau
aggregation.
Cavedo et al. (2018) [60] Memory complaints 18F-flortaucipir
-PET
FDG-PET
MRI
Cross-
sectional
Women: n=201(76.02±3.24)
Men:
n=117(76.05±3.85)
Men had higher amyloid
load glucose hypometabolism
and lower RSFC.
Gardener et al. (2016) [58] 1 binary question FDG-PET Cross-
sectional
All: n=43(66±10.1)
Non-SMC:
n=23(66±8.9)
SMC:
n=20 (68±11.4)
Positive association between
memory immediate recall and
FDG-PET SUVR in the right
amygdala in SMC individuals.
Matias-Guiu et al. (2017)
[61]
Memory complaint FDG-PET Cross-
sectional
HC: n=20(65.0±10.6)
SMC: n=9(72.4±10.6)
FCSRT positively correlate
with metabolism in the medial
and anterior temporal region
bilaterally, the left precuneus,
and posterior cingulate; BNT
results correlate with metabolism
in the middle temporal, superior,
fusiform, and frontal medial gyri
bilaterally; VOSP results relate to
the occipital and parietotemporal
regions bilaterally; ToL scores
correlate to metabolism in the
right temporoparietal and
frontal regions
Mosconi et al. (2008) [55] Structured interview FDG-PET Cross-
sectional
SMC- ApoE ɛ4-: n=7(63±5)
SMC+ ApoE ɛ4-: n=8(60±9)
SMC- ApoE ɛ4+: n=7(54±9)
SMC+ ApoE ɛ4+: n=6(59±7)
ApoE ɛ4+ carriers had decreased
CMRglc and higher CSF IP,
P-Tau, T-Tau, and P-Tau/Amyloid42
levels. SMC had reduced CMRglc.
ApoE genotype and SMC interacted
on lowest PHG CMRglc and the
highest CSF IP, P-Tau, and P-Tau/
Amyloid42 levels.
Scheef et al. (2012) [59] Memory clinic consultation
1 binary question
FDG-PET
MRI
Cross-
sectional
NC: n=56(66.4±7.2)
SMI: n=31(67.6±6.2)
SMI had hypometabolism in
the right precuneus and
hypermetabolism in the right
medial temporal lobe and
gray matter atrophy in the
right hippocampus. Association
between longitudinal memory
decline and reduced glucose
metabolism in the right
precuneus at baseline.
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HCs. The findings have converged to suggest that SCD
is associated with a significant reduction in the volume
of the cholinergic basal forebrain and the CA1 region of
the hippocampus compared with HCs [87–90]. In
addition to a reduced subcortical volume, a thinner cor-
tex, particularly in the temporal-parietal lobe, was asso-
ciated with a more rapid memory deterioration and an
increased risk of disease progression in subjects with
SCD compared with HCs [91–94].
Interestingly, Peter et al. [95] used a multivariate pat-
tern analysis (MVPA) to summarize the structural im-
aging profile of a subject into a single meaningful value
via a multivariate classification framework. The re-
searchers trained a classifier to separate individuals with
dementia due to AD from HCs and found that the gray
matter atrophy pattern of a subject with SCD was similar
to the brain of a patient with dementia due to AD but
was significantly different from an HC. The voxels with
greatest contributions to the classification were mainly
distributed in hippocampal and parahippocampal areas.
The findings of the study by Peter and colleagues sug-
gested that the multivariate analysis may represent a
powerful method for detecting subtle and distributed
changes in the early stages of AD.
Using brain network modeling methods, a gray matter
network can be constructed by calculating the structural
covariance between pairs of regions. According to previ-
ous studies, gray matter networks of patients with de-
mentia due to AD tend to be more randomly organized
with lower clustering coefficients and altered small-
world properties [96–98], suggesting that AD may be a
disconnection syndrome. Recently, Verfaillie et al. [99]
and Tijms et al. [100] have reported altered patterns of
gray matter networks in individuals with SCD that are
similar to patients with dementia due to AD. Both
groups of researchers showed that the gray matter net-
work of individuals with SCD was more randomly orga-
nized than HCs, and the disrupted network properties
were associated with a steeper decline in global cogni-
tion and a higher risk of disease progression. More-
over, Ten Kate et al. [101] observed an association
between a higher level of global amyloid deposition
and lower clustering and fewer small-world properties
of gray matter structural networks in subjects with
SCD. Overall, although some negative results have
been reported, individuals with SCD related to AD
have been repeatedly shown to present a reduced gray
matter volume and cortical thickness and a disrupted
gray matter network.
White matter
Diffusion tensor imaging (DTI) has been increasingly
applied to investigate microstructural alterations in
the WM of patients with a neurodegenerative disease
[102], which might reflect the pathological alterations
of WM degeneration, such as axon loss, damage or
demyelination. For patients with MCI and dementia
due to AD, widespread disruptions with decreased
fractional anisotropy (FA) and increased mean diffu-
sivity (MD), particularly in the cingulum bundles and
corpus callosum, and significant topological alter-
ations of the brain structural connectome have been
consistently reported [103–108].
In individuals with SCD, significantly decreased FA
and increased MD have been observed in the cerebrum,
mainly in the hippocampal body, entorhinal cortex and
parahippocampal gyrus, uncinated fasciculi, longitudinal
fasciculi and corpus callosum [77, 78, 109–113], whereas
Kiuchi et al. and Viviano et al. reported no statistically
significant differences in diffusion metrics [114, 115].
Various reasons for the discrepancy are plausible, in-
cluding different operational definitions of SCD and
differences in other factors (e.g., medication noncompli-
ance, blood pressure, and scanner differences). Interest-
ingly, by performing a whole-brain voxelwise analysis,
Selnes et al. [116] found increased radial diffusivity (RD)
Table 1 Summary of PET studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Song et al. (2016) [56] Memory complaint FDG-PET
MRI
Cross-
sectional
HC: n=42(68.02±5.44)
SMI: n=31(69.94±6.44)
MCI: n=47(69.55±6.65)
SMI had hypometabolism in
the periventricular regions.
SMI had hypometabolism in
the parietal, precentral frontal,
and periventricular regions.
Vannini et al. (2017) [57] MFQ PiB-PET
FDG-PET
Cross-
sectional
All: n=251(73.3±6.2)
amyloid-: n=190(72.8±6.1)
amyloid+: n=61(74.9±6.2)
Correlation between SMCs
and FDG metabolism. SMCs
interacted with amyloid
burden on FDG metabolism
in the bilateral medial
temporal lobes.
SCC Subjective cognitive complaints, ND Neurodegeneration, FDG 18F-Fluorodeoxyglucose, MAC-Q Memory assessment clinics questionnaire, SMD Subjective
memory decline, FTP Flortaucipir, SCD Subjective cognitive decline, CDR Clinical dementia rating, AD Alzheimer’s disease, SMI Subjective memory impairment,
CMRglc Cerebral metabolic rates for glucose, ApoE Apolipoprotein E, FCSRT Free and cued selective reminding test, BNT Boston naming test, VOSP Visual object and
space perception battery, ToL Tower of London test, CSF Cerebrospinal fluid, IP Isoprostane, SUVR Standardized uptake value ratio, SCI Subjective cognitive
impairment, MCI Mild cognitive impairment, NC Normal control, PET Positron emission tomography, PiB Pittsburgh compound B. ADNI: Alzheimer’s Disease
Neuroimaging Initiative, MRI Magnetic resonance imaging, MFQ Mood and Feelings Questionnaire, E-Cog Everyday Cognition Scale, RSFC Resting-state
functional connectivity
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and MD in widespread WM tracts but no changes in FA
in subjects with SCD. This finding may indicate that FA
is less sensitive than diffusivity metrics in revealing early
pathological processes. In addition, genetic risk factors
may aggravate degeneration in individuals with SCD. For
instance, compared with noncarriers, ApoE ɛ4 carriers in
SCD populations showed lower FA in the splenium of
the corpus callosum and the anterior corona radiata
[117]. Another investigation categorized individuals with
SCD into a high-risk group and a low-risk group based
on age, ApoE genotype, K-MMSE recall score and the
Seoul Verbal Learning Test. The high-risk group showed
more severe microstructural disruptions with reduced
FA in the tracts connecting the hippocampus, parahip-
pocampal gyrus, supramarginal gyrus and parts of the
frontotemporal lobes [118].
In contrast to the quantification of local diffusion met-
rics, other scholars have investigated the topological
organization of structural networks underlying SCD with
a graph theory analysis. As shown in the study by Shu
and colleagues, the SCD connectome exhibited lower
global and local efficiency and reduced rich-club and
local connections, which were correlated with impaired
memory performance in subjects with SCD [119]. Ac-
cording to Yan et al., only a limited number of periph-
eral regions and the connectivity among nonhub regions
were disrupted in patients with SCD, whereas rich-club
integration remained stable in the early stage of SCD but
subsequently progressed to exhibit disruptions associ-
ated with MCI and dementia due to AD [120]. Overall,
topological measures of the brain structural connectome
are sensitive metric of the early stage of AD, which es-
tablishes them as potential imaging markers of SCD.
The relationship between gray matter and WM alter-
ations in subjects with SCD remains largely unknown.
Research combining MRI volumetric and DTI measures
suggested that individuals with SCD showed a lower en-
torhinal cortical volume, lower FA and higher MD in
the hippocampal body and entorhinal WM [78]. Accord-
ing to another study [118], individuals with SCD with a
high risk of progression had more severe WM disruption
than the low-risk SCD group but no evident gray matter
atrophy. Thus, relatively high-risk SCD may predict an
underlying microstructural disruption in the WM that
precedes gray matter atrophy during AD progression.
However, during the SCD stage, the order of gray matter
or WM alterations and the relationship between them
require further investigation and elucidation to help us
obtain a better understanding of the pathological mecha-
nisms underlying AD development. The combination of
multiple MRI modalities provides the opportunity to
characterize biomarker features at different disease
stages and precisely track the progression of neurode-
generative alterations (Table 2).
Functional MRI
Resting-state fMRI
Resting-state fMRI (rs-fMRI) is a noninvasive technique
that detects alterations of spontaneous brain activity and
interregional functional connectivity (FC) by measuring
intrinsic blood oxygen level-dependent (BOLD) low-
frequency signal fluctuation. Based on accumulating evi-
dence, the FC of the default mode network (DMN) is se-
lectively disrupted in patients with MCI and dementia
due to AD [52, 129, 130]. The DMN can be detected in
a resting state and plays an important role in episodic
memory processing, self-reference, social cognition and
overall brain function [131–133]. The DMN consists of
a set of highly interconnected brain regions, including
the posterior cingulate cortex, medial prefrontal cortex,
lateral temporoparietal cortices and the hippocampus
[134]. Importantly, these regions are among the earliest
locations to show gray matter atrophy, hypometabolism
and amyloid deposition during the initiation of AD
pathology.
For subjects with SCD, our group reported a higher
amplitude of low-frequency fluctuations (ALFF) of
spontaneous brain activity in the left inferior parietal
lobule and right middle occipital gyrus and a lower
ALFF in the precuneus and cerebellum than in HCs
[122, 135]. The alterations in ALFF were correlated
with the verbal episodic memory scores of subjects
with SCD [122]. The increased ALFF in SCD subjects
may reflect a compensatory mechanism for functional
deficits in the preclinical stage of AD. Yang et al. ob-
served a higher accuracy of discriminating individuals
with SCD from HCs when ALFF and fractional ALFF
features were combined than when only single fea-
tures were used [135].
Other studies have focused on the alterations in intrin-
sic functional networks. Subjects with SCD exhibited
higher FC in the retrosplenial cortex and precuneus and
lower FC in the frontal-parietal cortex and putative pos-
terior memory system [115, 136, 137]. As an important
potential biomarker, the DMN has also received increas-
ing attention in individuals with SCD. However, the re-
sults remain heterogeneous. In terms of connectivity
between the DMN and other regions, Verfaillie et al.
[128] found increased connectivity between the posterior
DMN and the medial temporal memory system in sub-
jects with SCD; in contrast, decreased connectivity be-
tween the DMN and hippocampus was observed in
individuals with SCD in another study [138]. Regarding
the connectivity within the DMN, one study reported re-
duced DMN connectivity in individuals with SCD rela-
tive to HCs [139], conflicting with the findings of
another study [73]. In addition, Yasuno and colleagues
reported reduced FC in cortical midline structures where
some of the DMN regions are located in individuals with
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Table 2 Summary of structural and diffusion MRI studies
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Jessen et al. (2006) [81] Memory clinic consultation
for < 5 y SCD
T1 MRI Cross-sectional NC: n = 14 (66.5 ± 6.4)
SCD: n = 12 (66.1 ± 7.3)
MCI: n = 15 (68.2 ± 5.5)
AD: n = 13 (68.8 ± 9.7)
Atrophy in entorhinal cortex not
in hippocampus.
Saykin et al. (2006) [79] Consensus evaluation using a
composite index (multiple
self and informant-based
questionnaires)
T1 MRI Cross-sectional NC: n = 40 (71.0 ± 5.1)
SCD: n = 40 (73.3 ± 6.0)
MCI: n = 40 (72.9 ± 7.1)
Decreased gray matter in the
MTL, frontotemporal and other
neocortical regions in SCD and
MCI. reduced hippocampal
volumes only in MCI.
Nunes et al. (2010) [75] Memory clinic consultation T1 MRI Longitudinal
(NC: 3.4 years
SCD: 3.4 years
MCI: 3.7 years)
NC: n = 11 (69.5 ± 5.5)
SCD: n = 15 (65.9 ± 7.7)
MCI: n = 17 (70.8 ± 6.4)
SCD had decreased hippocampal
volume longitudinal. MCI had
decrease both in total
hippocampal and amygdala
volumes.
Shen et al. (2010) [80] Consensus evaluation using a
composite index (multiple
self and informant-based
questionnaires)
T1 MRI Cross-sectional NC: n = 38 (70.6 ± 5.2)
SCD: n = 39 (72.8 ± 6.1)
MCI: n = 37 (72.7 ± 7.1)
AD: n = 11 (75.6 ± 6.8)
Both MCI group and the AD
dementia group showed
hippocampal volume reduction
compared to NC and SCD.
Striepens et al. (2010) Memory clinic consultation
for <10 y SCD, informant
confirmed
T1 MRI Cross-sectional NC: n = 48 (66.3 ± 6.2)
SCD: n = 21 (65 ± 7.2)
The SCD had reduced volume of
bilateral hippocampus, the
bilateral entorhinal cortex and
the right amygdala compared to
the NC.
Stewart et al. (2011) [86] 2 binary questions (SCD
when both positive)
T1 MRI Longitudinal
(4 years)
Baseline SCD: n = 1793
(72.4 ± 4.1)
Follow-up SCD: n = 1336
(72.0 ± 4.0)
SCD at baseline was associated
with subsequent change in
hippocampal volume and at
follow-up impairment was
associated with previous
change in hippocampus,
CSF and gray matter volume.
Striepens et al. (2011) [84] Memory clinic consultation
for <10 y SCD, informant
confirmed
T1 MRI Cross-sectional NC ApoE ɛ4+: n = 16
(65.9 ± 7.2)
NC ApoE ɛ4-: n = 56
(67.4 ± 7.7)
SCD ApoE ɛ4+: n = 11
(66.8 ± 6.8)
SCD ApoE ɛ4-: n = 30
(68.5 ± 7.2)
ApoE ɛ4 carriers with SMI
performed worse on the episodic
memory and showed smaller left
hippocampal volumes. The ApoE
ɛ4 carriers without SMI
performed better on episodic
memory and had larger right
hippocampal volumes.
Scheef et al. (2012) [59] Memory clinic consultation
for <10 y SCD with worry,
informant confirmed
T1 MRI; Longitudinal
(NC: 34.6 months
SCD: 35.5 months)
Baseline
NC: n = 56 (66.4 ± 7.2)
SCD: n = 31 (67.6 ± 6.2)
Follow-up
NC: n = 48 (66.5 ± 7.2)
SCD: n = 27 (67.4 ± 6.5)
SCD had reduced gray
matter volume in the right
hippocampus.
Kim et al. (2013) [68] Reason for seeking help:
memory or health
promotion?
T1 MRI Cross-sectional NC: n = 28 (70.7 ± 5.5)
SCD: n = 90 (65.8 ± 8.5)
The SCD showed significantly
smaller hippocampal and
amygdala volumes. Association
between lower GDS score and
smaller hippocampal volume
SCD, and association between
higher GDS score and smaller
amygdala volume NC.
Peter et al. (2014) [95] Memory clinic consultation
for <10 y SCD with worry,
informant confirmed
T1 MRI Cross-sectional NC: n = 53 (67.1 ± 6.1)
SCD: n = 24 (66.0 ± 7.1)
SCD showed greater similarity to
a dementia gray matter pattern
compared with NC. Association
between episodic memory
decline and a dementia gray
matter pattern in SCD.
Cherbuin et al. (2015) [76] 1 binary question T1 MRI Longitudinal
(4 years)
NC: n = 218 (62.7 ± 1.32)
W1 SCD: n = 70 (62.1 ± 1.4)
W2 SCD: n = 56 (62.4 ± 1.5)
W1 + W2 SCD: n = 39 (62.3
± 1.4)
SCD at baseline was not
associated with hippocampal
atrophy. SCD at follow-up was
associated with greater hippo
campal atrophy.
Meiberth et al. (2015) [91] Memory clinic consultation
for <10 y SCD, informant
confirmed
T1 MRI Cross-sectional NC: n = 69 (66.1 ± 6.9)
SCD: n = 41 (68.9 ± 7.2)
SCD showed thickness reduction
in left entorhinal cortex
compared to NC.
Perrotin et al. (2015) [88] Memory clinic consultation T1 MRI Cross-sectional NC: n = 40 (69.4 ± 6.4)
SCD: n = 17 (69.1 ± 8.5)
AD: n = 21 (68.3 ± 9.5)
SCD showed TIV-normalized vol
ume decrease in hippocampus
compared to NC.
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Table 2 Summary of structural and diffusion MRI studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Schultz et al. (2015) [92] 1 binary question T1 MRI Cross-sectional SCD: n = 77 (54.3 ± 6.1)
NC: n =184 (54.4 ± 6.4)
SCD showed cortical thinning in
the entorhinal, fusiform, posterior
cingulate, and inferior parietal
cortices and reduced amygdala
volume compared with NC
Cantero et al. (2016) [87] Questionnaire, structured
interview
T1 MRI Cross-sectional NC: n = 47 (68.1 ± 3.2)
SCD: n = 48 (69.6 ± 4.3)
SCD showed decreased volumes
of CA1, CA4, dentate gyrus and
molecular layer compared to NC.
Lower volume of the dentate
gyres associates with poorer
memory performance.
Hong et al. (2016) [118] Memory clinic consultation T1 MRI
DTI
Cross-sectional Low risk: n = 27 (62.1 ± 7.1)
High risk: n = 19 (67.1 ± 6.5)
The high-risk group showed
lower FA in the hippocampus,
parahippocampal gyrus, supra
maiginal gyrus and parts of
fronto-temporal lobes, but no
gray matter atrophy.
Jung et al. (2016) [121] Memory clinic consultation T1 MRI Cross-sectional SMI: n=612(64.9 ± 6.9) Individuals with different subtype
atrophy showed difference in
age, gender, vascular risk factors
and depression. Combination of
these factors classified the
temporal atrophy subtype and
the minimal atrophy subtype
with 73.2% and 76.0% accuracy.
Lee et al. (2016) [117] Memory clinic consultation T1 MRI
DTI
Cross-sectional ApoE ɛ4+: n = 13
(66.4 ± 6.3)
ApoE ɛ4-: n = 13
(66.2 ± 7.8)
ApoE ɛ4+ SCD showed gray
matter atrophy and lower FA
compared with ApoE ɛ4- SCD.
Rogne et al. (2016) [69] 1 binary question T1 MRI Cross-sectional NC: n = 58 (70.6 ± 6.7)
SCD: n = 25 (70.0 ± 9.1)
MCI: n = 115 (74.5 ± 7.5)
SCD had larger lateral ventricles
and smaller hippocampal
volumes than NC.
Sun et al. (2016) [122] Memory clinic consultation T1 MRI
rs-fMRI
Cross-sectional NC: n = 61 (64.1 ± 8.6)
SCD: n = 25 (65.5 ± 6.1)
SCD showed higher ALFF but no
differences in gray matter
volume
Verfaillie et al. (2016) [93] Memory clinic consultation T1 MRI Cross-sectional SCD stable: n = 253 (61 ± 9)
SCD progression: n = 49
(69 ± 6)
Hippocampal volumes, thinner
cortex of the AD-signature and
various AD-signature
subcomponents were
associated with increased
risk of clinical progression
Lauriola et al. (2017) [123] Subjective cognitive decline
Questionnaire
T1 MRI Cross-sectional NC: n = 38 (64.0 ± 5.1)
SCD: n = 32 (64.8 ± 6.3)
SCD showed increased nighttime
wakefulness and reduced sleep
efficiency.
Norton et al. (2017) [124] Memory Complaint Scald in
Spanish
T1 MRI Cross-sectional Noncarriers: n = 26
(37.2 ± 6.5)
Carriers: n = 26 (35.6 ± 7.7)
PSEN-1 E280A mutation carrier
showed decreased hippocampal
volume in SCD compared to
noncarriers.
Perrotin et al. (2017) [23] Memory clinic consultation 18F-florbetapir
PET and T1
MRI
Cross-sectional NC: n = 35 (65.8 ± 8.6)
SCD community: n = 35
(70.8 ± 7.5)
SCD clinic: n 28 (67.6 ± 7.7)
SCD showed increased amyloid
deposition. Subclinical
depression and hippocampal
atrophy were associated with
medical help seeking.
Risacher et al. (2017) [125] Cognitive change Index 18F-florbetapir
and T1 MRI
Cross-sectional NC: n = 19 (68.5 ± 6.9)
SCD: n = 10 (72.2 ± 6.4)
MCI: n = 5 (75.7 ± 10.6)
Lower UPSIT scores were
associated with increased
temporal, parietal tau burden
and temporal lobe atrophy in the
full sample and in NC and SCD only.
Hafkemeijer et al. (2013) [73] Memory clinic consultation T1 MRI Cross-sectional NC = 29 (71.3 ± 3.6)
SCD: n = 25 (71.4 ± 9.2)
Reduced gray matter volume in
DMN regions.
Platero et al., (2019) [82] SCD-I Working Group T1 MRI Cross-sectional NC: n = 70 (70.3 ± 4.5)
SCD: n = 87 (71.7 ± 5.1)
MCI: n = 137 (73.9 ± 5.0)
AD: n = 13 (75.6 ± 5.0)
No differences in hippocampal
volumes between NC and SCD.
Sanchez-Benavid et al.,
(2018) [72]
1 binary question and
SCD-Q questionnaire
T1 MRI Cross-sectional NC: n = 2098 (55.41 ± 6.62)
SCD-: n = 319 (55.62 ± 6.22)
SCD+: n = 253 (59.10 ± 7.12)
SCD+ subjects showed lower
gray matter volumes.
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Table 2 Summary of structural and diffusion MRI studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Sun et al., (2019) [85] Memory clinic consultation for <
5 y SCD
T1 MRI Cross-sectional NC: n = 73 (64.55 ± 5.52)
SCD: n = 65 (65.85 ± 4.85)
Decreased total cortical volumes
and cortical surface area in SCD.
SCD ApoE ɛ4 carriers showed
additive reduction in the right
cortical surface area.
Tepest et al., (2018) [83] Memory clinic consultation T1 MRI Cross-sectional NC: n = 13 (67.5 ± 5.5)
SCD: n = 14 (66.4 ± 7.3)
MCI: n = 15 (68.2 ± 5.4)
AD: n = 12 (69.2 ± 10.0)
No differences in hippocampal
surface between SCD and NC.
Tijms et al., (2018) [100] Memory clinic consultation T1 MRI Cross-sectional sSCD: n = 100 (67 ± 8)
pSCD : n = 122 (68 ± 8)
Lower network parameter values
related with increased risk for
progression.
Rooden et al., (2018) [74] Memory clinic consultation T1 MRI Cross-sectional NC: n = 42 (68 ± 9.2)
SCD: n = 25 (68 ± 9.1)
SCD showed hippocampal
atrophy.
Zhao et al., (2019) [89, 126] SCD-I Working Group T1 MRI Cross-sectional NC: n = 42 (64.24 ± 6.16)
SCD: n = 35 (64.53 ± 7.29)
aMCI: n = 43 (67.47 ± 10.03)
AD: n = 41 (68.88 ± 7.86)
No difference in hippocampal
volume between NC and SCD.
Ryu et al. (2017) [78] Memory clinic consultation T1 MRI
and DTI
Cross-sectional NC: n = 27 (70.6 ± 6.1)
SCD: n = 18 (69.9 ± 6.3)
SCD showed lower entorhinal
cortical volumes and lower
FA and higher MD in the
hippocampal body and
entorhinal WM compared
with NC.
Fan et al. (2018) [77] Memory clinic consultation T1 MRI
and DTI
Cross-sectional NC: n = 34 (67.8 ± 7.4)
SCD: n = 43 (66.1 ± 7.0)
aMCI: n = 44 (73.9 ± 8.0)
SCD showed cortical atrophy
and decreased mean FA.
Niemantsverdriet et al.
(2018) [127]
Criteria by SCD-I T1 MRI Cross-sectional NC: n = 93 (67.3 ± 8.5)
SCD: n = 102 (68.6 ± 9.8)
MCI: n = 379 (74.6 ± 8.0)
AD: n = 313 (77.5 ± 8.0)
Baseline whole brain, gray
matter, cortical gray matter and
increased CSF volumes predicted
cognitive impairment
Verfaillie et al. (2018) [94, 99,
128]
Referred by general
practitioners or medical
specialists
T1 MRI Cross-sectional SCD: n = 233 (52.8 ± 9.2) SCD with faster subsequent
memory loss was associated with
thinner cortex of the frontal and
occipital cortices.
Verfaillie et al. (2018) [94, 99,
128]
Memory clinic consultation T1 MRI Cross-sectional SCD: n = 231 (63.0 ± 9.2) SCD with lower network size was
associated with steeper decline
in language.
Yue et al. (2018) [71] 1 binary questions T1 MRI Cross-sectional NC: n = 67 (67.7 ± 6.6)
SCD: n =111 (69.8 ± 7.6)
MCI: n = 30 (75.5 ± 7.6)
The SCD showed decreased right
hippocampal and amygdala
volume than NC. Right
hippocampal and amygdala
volume was correlated
to MMSE and MoCA in SCD.
Lee et al. (2016) [117] Memory clinic consultation T1 MRI
DTI
Cross-sectional ApoE ɛ4+: n = 13 (66.4 ± 6.3)
ApoE ɛ4-: n = 13 (66.2 ± 7.8)
ApoE ɛ4+ SCD showed gray
matter atrophy and lower FA
compared with ApoE ɛ4- SCD.
Brueggen et al., (2019) [111] Memory clinic consultation T1 MRI, DTI Cross-sectional NC: n = 93 (68.5 ± 5.1)
SCD: n = 98 (71.3 ± 5.9)
MCI: n = 45 (72.3 ± 5.7)
AD: n = 35 (73.5 ± 6.8)
SCD showed higher MD, lower
MO and FA.
Kiuchi et al., (2014) [114] Memory clinic consultation T1 MRI, DTI Cross-sectional NC: n = 41 (75.2 ± 5.34)
SCD: n = 28 (70.5 ± 7.30)
MCI: n = 43 (74.6 ± 6.40)
AD: n = 39 (73.2 ± 7.98)
No differences between
NC and SCD.
Li et al., (2016) [109] SCD-I Working Group DTI Cross-sectional NC: n = 37 (65.1 ± 6.8)
SCD: n = 27 (65.3 ± 8.0)
aMCI: n = 35 (69.2 ± 8.6)
AD: n = 25 (68.3 ± 9.4)
SCD showed decreased FA,
increased MD and RD.
Ohlhauser et al., (2019) [112] Cognitive Change Index test Cross-sectional NC: n = 44 (72.49 ± 6.37)
SCD: n = 30 (72.94 ± 4.79)
SCD showed lower WM integrity
and DTI metrics related with
executive function in SCD.
Viviano et al., (2019) [115] Memory clinic consultation Cross-sectional NC: n = 48 (66.96 ± 8.79)
SCD: n = 35 (68.51 ± 7.66)
No differences in diffusion
measures between SCD and NC
Yasuno et al., (2015) [113] Memory clinic consultation Cross-sectional NC: n = 30 (72.2 ± 4.8)
SCD: n = 23 (69.6 ± 8.0)
SCD showed reduced WM
connections.
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SCD [113]. Furthermore, some studies also explored the
interactions of SCD with other risk factors for dementia
due to AD and their effects on FC. Cavedo et al. [60]
found sex-specific alterations in the resting state (FC) of
the DMN. The study conducted by Chiesa et al. revealed
that ApoE ɛ4 carriers presented a slower longitudinal in-
crease in FC in the frontal lobes than noncarriers [140].
Overall, these findings indicate an important role for the
functional network, particularly the DMN, in SCD, sug-
gesting that the DMN may represent a specific target for
the early intervention and treatment of AD, although
these results are heterogeneous and more studies based
on rs-fMRI are needed to explore the role of the DMN
in SCD.
Task-based fMRI
Task-based fMRI has been widely used to explore changes
in functional activity during different cognitive tasks by
examining the changes in BOLD signals. Medial temporal
lobe hypoactivation, parietal hyperactivation, and frontal
hyperactivation during memory tasks have been reported
in patients with MCI and dementia due to AD [141–144].
Task-based fMRI studies of subjects with SCD remain
scarce, and the current findings are controversial.
In one study, subjects with SCD showed increased ac-
tivation in the middle frontal gyrus, the precuneus and
the cingulate gyrus relative to HCs during working
memory tasks [145]. However, a different effect was ob-
served in another study [146], which showed that SCD
was associated with reduced activation in the right
hippocampus and increased activation in the right
dorsolateral prefrontal cortex during an episodic mem-
ory recall task. In addition, Rodda et al. reported in-
creased activation in the prefrontal cortex, left medial
temporal lobe, bilateral thalamus, posterior cingulate
and caudate of individuals with SCD during the encod-
ing of novel words and a divided attention task [147,
148]. Notably, these regions displaying greater activa-
tion during different tasks were proposed to be mainly
involved in the DMN, which may reflect the deploy-
ment of some compensatory processes. However, re-
searchers have not yet clearly determined whether
these differences are specific to successful memory en-
coding or related to general cognitive processes. Hayes
and colleagues applied a subsequent memory paradigm
to examine potential differences in the subsequent
memory effect between cognitively intact older adults
with and without SCD [149]. The researchers found
that SCD was associated with more limited subsequent
memory effects on the occipital lobe, superior parietal
lobe, and posterior cingulate cortex and more disrupted
subsequent memory effects on areas of the DMN.
Interestingly, Hu and colleagues identified an associ-
ation between increased delay discount in individuals
with SCD and changes in the brain network related to
episodic memory [150]. Hence, the altered functional
activation patterns observed during memory tasks may
indicate brain functional reorganization due to SCD.
However, some advanced modeling approaches, such as
dynamic causal modeling, should be productively ap-
plied to investigate early functional alterations in indi-
viduals with SCD.
Table 2 Summary of structural and diffusion MRI studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Selnes et al (2012) [116] Memory clinic consultation T1 MRI
and DTI
Cross-sectional NC: n = 21 (49 - 77)
SCD: n = 16 (45 - 71)
MCI: n = 50 (45 - 77)
SCD had higher DR and MD in
posterior cingulate, retrosplenial
and middle cortices.
Shu et al (2018) [119] Memory clinic consultation DTI Cross-sectional NC: n = 51 (62.2 ± 9.1)
SCD: n = 36 (63.5 ± 8.7)
SCD had lower global and local
efficiency and reduced rich-club
and local connections which
were correlated with the
impaired memory
performance.
Wang et al. (2012) [110] Memory clinic consultation DTI Cross-sectional NC: n = 35 (71.6 ± 5.2)
SCD: n = 29 (73.4 ± 6.3)
MCI: n = 28 (74.3 ± 5.8)
SCD had FA, DR, DA and MD
values that
were intermediate to the MCI
and NC.
Yan et al. (2018) [120] Memory clinic consultation DTI Cross-sectional NC: n = 62 (63.3 ± 8.1)
SCD: n = 47 (65.3 ± 8.4)
aMCI: n = 60 (67.3 ± 9.4)
d-AD: n = 55 (70.9 ± 9.8)
SCD showed disrupted
peripheral regions and reduced
connectivity similar to MCI and
dementia due to AD. The rich
club organization remain stable
in the earliest stage only in SCD
SCC Subjective cognitive complaints, ND Neurodegeneration, SMD Subjective memory decline, FTP Flortaucipir, SCD Subjective cognitive decline, CDR Clinical
dementia rating, AD Alzheimer’s disease, SMI Subjective memory impairment, CMRglc Cerebral metabolic rates for glucose, ApoE Apolipoprotein E, FCSRT Free and
cued selective reminding test, BNT Boston naming test, VOSP Visual object and space perception battery, ToL Tower of London test, CSF Cerebrospinal fluid, IP
Isoprostane, SUVR Standardized uptake value ratio, SCI Subjective cognitive impairment, MCI Mild cognitive impairment, aMCI Amnestic MCI, NC Normal control,
PET Positron emission tomography, ADNI Alzheimer’s Disease Neuroimaging Initiative, MRI Magnetic resonance imaging, DTI Diffusion tensor imaging, WM White
matter, FA Fractional anisotropy, MD Mean diffusivity, RD Radial diffusivity, rs-fMRI Resting-state functional MRI, DMN Default mode network
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Arterial spin labeling
Arterial spin labeling (ASL) MRI is a noninvasive tech-
nique for quantifying cerebral perfusion that has been
implicated as a useful biomarker of the early stages of
AD [151]. Patients with MCI exhibit hypoperfusion in
the temporal parietal cortex [152–155], and patients
with dementia due to AD present with decreased cere-
bral blood flow (CBF) in a wide range of brain areas
[152, 156–159] compared with cognitively normal adults.
In addition, some studies even reported that cognitively
normal adults with the ApoE ɛ4 allele [154, 160, 161]
and a maternal family history of AD [152] had an altered
CBF (including a greater decrease in CBF over time, re-
duced CBF and increased resting-state CBF) compared
with controls.
However, fewer ASL-MRI studies of individuals with
SCD are available. To the best of our knowledge, only
two studies have explored the differences in CBF be-
tween individuals with SCD and HCs. According to Hays
et al., patients with SCD exhibited lower CBF in the
medial orbitofrontal cortex and higher CBF in the right
putamen than HCs [162], while de Eulate et al. did not
observe any differences in total blood flow between indi-
viduals with SCD and HCs [163].
The results for the relationship between cognition and
CBF are also inconsistent. Hays et al. observed negative
association between verbal memory and CBF within the
posterior cingulate cortex, middle temporal gyrus,
hippocampus, fusiform gyrus and inferior frontal gyrus
in patients with SCD [162], while Leeuwis et al. did not
observed correlation between CBF and cognition in pa-
tients with SCD [164].
These controversial results may be due to the use of
different cohorts and image processing methodologies.
Hays et al. used voxelwise statistics among community-
dwelling older volunteers, and the other two studies fo-
cused on defined ROI regions in the Amsterdam De-
mentia Cohort. In summary, ASL-MRI has vast potential
as a biomarker of SCD, but additional studies using this
modality are needed (Table 3).
EEG/MEG
Electroencephalography (EEG) and magnetoencepha-
lography (MEG) are noninvasive techniques that rec-
ord the electrical activity and magnetic fields
generated by neuronal activity in the brain, respect-
ively. During the last few decades, many studies have
investigated the alterations in EEG and/or MEG sig-
nals in patients with MCI and dementia due to AD
and have reported slowing brain rhythms and abnor-
mal FC in the patients [166–169].
While the advanced stages of AD may be associated
with functional disconnection [170], earlier stages may
be apparent in terms of spectral measures and cortical
rhythms detected using EEG [171–173]. Indeed, spectral
data have shown a higher alpha power in patients with
SCD that was most strongly correlated with a decline in
verbal memory performance and the working memory
reaction time [171]. In addition, Gouw et al. [173] re-
ported association between abnormal delta, theta and
alpha power and alpha peak frequency with clinical
progression. In addition, amplitude abnormalities in
delta, theta, and alpha rhythms have been recorded
for individuals with SCD compared with HCs, sug-
gesting that individuals with SCD present an abnor-
mal pattern of dominant cortical alpha rhythms [172].
Furthermore, when separating individuals with SCD
into decliners and nondecliners based on whether
cognition decreased longitudinally, decliners showed
increases in theta power, slowing of the mean fre-
quency and changes in covariance among regions,
particularly in the right hemisphere [174].
Using MEG, researchers have observed a significant al-
teration in spontaneous alpha activity in elderly partici-
pants with SCD, and this alteration was related to a
decrease in cognitive performance [175]. An increase in
brain activation in subjects with SCD and MCI during a
memory task has also been reported [176]. Then, based
on connectivity-based analyses, researchers revealed that
participants with MCI and SCD exhibited a very similar
pattern of alterations combining hypersynchronization
over anterior brain regions (affecting the connection be-
tween the cingulate gyrus, frontal regions and anterior
temporal areas) and hyposynchronization affecting more
posterior areas (including parietal and medial temporal
structures and occipital regions) [168]. Furthermore,
subjects with SCD showed decreased clustering and
transitivity in theta and beta bands, but increased modu-
larity and transitivity in the alpha band, based on a graph
theory analysis [177].
Overall, the aforementioned evidence supports the hy-
pothesis that EEG/MEG measures play important roles
in detecting early functional brain alterations in individ-
uals with SCD and may serve as early imaging bio-
markers of AD initiation (Table 4).
Multimodal neuroimaging studies
Multimodal neuroimaging techniques combing PET and
MRI have been used with increasing frequency to im-
prove our understanding of the pathological interactions
underlying SCD due to AD [179]. Abnormal amyloid
pathology is earliest pathological change and triggers
downstream neurodegeneration events [2]. A between-
group analysis performed by Chetelat et al. indicated
that, in participants with SCD, individuals with a higher
level of amyloid deposition showed significant gray mat-
ter atrophy compared with individuals with a low level
of amyloid deposition [180]. Further correlation analyses
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Table 3 Summary of functional MRI studies
Authors Definition of SCD Modality Design Sample
(mean age ± SD)
Main findings
Dummas et al.
(2013) [145]
Endorsed more than 20% of
the items on the complaint
inventory
Task-fMRI Cross-sectional NC: n = 11 (56.8 ± 1.9)
SCD: n = 12 (57.1 ± 2.3)
SCD had increased activations in
middle frontal gyrus, precuneus
and cingulate gyrus compared
to NC.
Erk et al. (2011) [146] Memory clinic consultation Task-fMRI Cross-sectional NC: n = 20 (66.8 ± 5.4)
SCD: n = 19 (68.4 ± 5.7)
SCD was associated with a
reduction in right hippocampal
activation during episodic
memory recall in the absence of
performance deficits and
increased activation of the right
dorsolateral prefrontal cortex.
Rodda et al. (2009) [147] Self-perceived memory
difficulties persistent and
severe enough to seek advice
despite normal cognition
Task-fMRI Cross-sectional NC: n = 10 (68.0 ± 13.5)
SCD: n = 10 (64.2 ± 5.6)
SCD exhibited increased
activation in left during the
divided attention task.
Hu et al. (2017) [150] Criteria by SCD-I Task-fMRI Cross-sectional NC: n = 24 (66.5 ± 7.2)
SCD: n = 20 (68.3 ± 7.9)
Subtle neuronal network
disruptions in SCD.
Hayes et al. (2017) [149] Worrisome decline in
memory
Task-fMRI Cross-sectional NC: n = 41 (67.5 ± 9.1)
SCD: n = 23 (68.6 ± 8.2)
SCD showed a more negative
subsequent memory effects in
the default mode network.
Dillen et al. (2017) [138] A cut-off value of≥25 on the
memory complaint
questionnaire but
average scores on
neuropsychological tests
rs-fMRI Cross-sectional NC: n = 25 (62.4 ± 7.0)
SCD: n = 28 (65.8 ± 7.8)
Prodromal AD: n = 25
(70.8 ± 6.2)
SCD showed decreased
connectivity between DMN
and hippocampus.
Hafkemeijer et al.
(2013) [73]
Memory complaints but
normal cognition
T1 MRI and
rs-fMRI
Cross-sectional NC: n = 29 (71.3 ± 3.4)
SCD: n = 25 (71.4 ± 9.2)
SMC showed increased FC in
the default mode network.
Sun et al. (2016) [122] Self-reported persistent
decline in memory compared
with a previous state but
normal cognition
T1 MRI and
rs-fMRI
Cross-sectional NC: n = 61 (64.1 ± 8.6)
SCD: n = 25 (65.5 ± 6.1)
SCD had higher ALFF values in
the left inferior parietal lobule
and right middle occipital gyrus
than control subjects, which
were correlated with verbal
episodic memory scores.
Verfaillie et al. (2018) [128] 1 binary question rs-fMRI Longitudinal
(one year)
Baseline NC: n = 56
(64 ± 5)
Baseline SCD: n = 68
(64 ± 5)
Follow-up NC: n = 29
(65 ± 6)
Follow-up SCD: n = 30
(65 ± 6)
SCD showed increased pDMN–
MTMS connectivity. Higher
connectivity between MTMS and
the rest of brain was associated
with better baseline immediate
memory, attention, and global
cognition. Higher
MTMS and pDMN–MTMS
connectivity were associated
with lower immediate memory
over time.
Wang et al. (2013) [139] Endorsed more
than 20% of the items
on the Cognitive
Complaint Index
rs-fMRI Cross-sectional NC: n = 16 (70.7 ± 6.0)
SCD: n = 23 (70.1 ± 7.3)
MCI: n = 18 (73.7 ± 9.1)
SCD showed decreased DMN
connectivity in the right
hippocampus compared to
NC and higher connectivity
compared to MCI.
Yasuno et al. (2015) [113] Reisberg criteria rs-fMRI Cross-sectional NC: n = 30 (72.2 ± 4.8)
SCD: n = 23 (69.6 ± 8.0)
SCD showed reduced FC in
cortical midline structures
Cavedo et al. (2018) subjective memory
complaints
18F-florbetapir-PET
FDG-PET
MRI
Cross-sectional Women: n=201
(76.02±3.24)
Men: n = 117(76.05±3.85)
Men had lower resting-state FC.
Chiesa et al., (2019) [140] 2 binary questions rs-fMRI Cross-sectional ApoE ɛ4+: 44 (75.6 ± 3.5)
ApoE ɛ4-: 180 (75.5 ± 3.4)
ApoE ɛ4+ showed slower
increase in FC in frontal lobes.
Dillen et al., (2016) [136] Structural questionnaire rs-fMRI Cross-sectional NC: n = 25 (62.4 ± 7.0)
SCD: n = 27 (65.7 ± 7.9)
AD: n = 24 (71.0 ± 6.2)
Higher FC from RSC to
frontal cortex in SCD.
Dong et al., (2018) [137] Memory clinic consultation rs-fMRI Cross-sectional NC: n = 39 (82.89 ± 4.13)
SCD: n = 39 (83 ± 4.43)
Lower aFCS in SCD.
Viviano et al., (2019) [115] 2 binary questions rs-fMRI Cross-sectional NC: n = 48 (66.96 ± 8.79)
SCD: n = 35 (68.51 ± 7.66)
SCD showed lower
average FC.
Eulate el al., (2017) [163] Memory clinic consultation ASL Cross-sectional NC: n = 32 (72.3 ± 5.6)
SCD: n = 28 (67.3 ± 7.8)
MCI: n = 34 (73.7 ± 7.5)
No differences in CBF
between SCD and HC.
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between imaging modalities also supported the relation-
ship between amyloid pathology and reduced integrity of
brain structures in both the gray matter and WM ran-
ging from voxel level to brain connectome properties in
subjects with SCD [101, 181, 182]. Ferreira et al. tested a
disease severity index generated from a multivariate ana-
lysis involving amyloid PET and structural MRI data,
and this index may potentially identify individuals with
Table 3 Summary of functional MRI studies (Continued)
Authors Definition of SCD Modality Design Sample
(mean age ± SD)
Main findings
AD: n = 21 (75.8 ± 6.2)
Hays et al., (2018) [162] Memory clinic consultation ASL Cross-
sectional
NC: n = 35 (73 ± 6.25)
SCD: n = 35 (72.54 ± 5.07)
SCD showed negative
associations between
verbal memory and CBF.
Leeuwis et a.,
(2017) [164]
Memory clinic consultation ASL Cross-
sectional
SCD: n = 143 (56.69 ± 8.69)
MCI: n = 95 (65.24 ± 7.28)
AD: n = 161 (65.93 ± 7.04)
No correlation between
CBF and cognition.
Yang et al., (2019) [165] SCD-I Working Group rs-fMRI Cross-
sectional
NC: n = 55 (63.41 ± 7.97)
SCD: n = 43 (65.09 ± 8.66)
aMCI: n = 52 (68.06 ± 9.32)
AD: n = 44 (70.98 ± 10.02)
SCD showed lower fALFF.
FDG 18F-Fluorodeoxyglucose, SCD Subjective cognitive decline, AD Alzheimer’s disease, MCI Mild cognitive impairment, aMCI Amnestic MCI, NC Normal control,
PET Positron emission tomography, MRI Magnetic resonance imaging, fMRI Functional MRI, rs-fMRI Resting-state fMRI, MTL Medial temporal lobe, ALFF Amplitude
of low-frequency fluctuations, fALFF Fractional ALFF, DMN Default mode network, pDMN Posterior DMN. SMC: Subjective memory complaints, MTMs Medial
temporal memory system, RSN Resting-state networks, VIS Visual, CCI Cognitive complaint index, ASL Arterial spin labeling, CBF Cerebral blood flow, SCD-I
Subjective Cognitive Decline Initiative, FC Functional connectivity, ApoE Apolipoprotein E
Table 4 Summary of EEG and MEG studies
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Alexander et al. (2006) [171] Memory clinic consultation EEG Cross-sectional NC: n = 79 (63.1 ± 7.9)
SCD: n = 100 (64.9 ± 8.7)
SCD showed higher alpha power
and changes in wave activity both
related to decreased memory.
Babiloni et al. (2010) [172] Memory clinic consultation EEG Cross-sectional NC: n = 79 (69.7 ± 0.9)
SCD: n = 53 (69.0 ± 1.0)
aMCI: n = 92 (72.0 ±)
naMCI: n = 51 (73.0 ± 1.1)
SCD showed greater frontal delta
sources and lower parietal and
occipital theta sources in
amplitude.
Gouw et al. (2017) [173] Criteria by SCD-I EEG Cross-sectional SCD: n = 63 (66.2 ± 8.2)
MCI: n = 142 (68.3 ± 7.4)
In SCD, higher delta and theta
power and lower alpha power
and peak frequency were
associated with clinical
progression
Teipel et al. (2018) [178] 2 binary questions EEG and 18F-
florbetapir-PET
Cross-sectional SCD amyloid-: n = 255
(75.9 ± 3.5)
SCD amyloid +: n = 63
(76.7 ± 3.5)
Amyloid accumulation does
not impair cortical FC in SCD.
Lopez-Sanz et al. (2016) [175] Self-reported cognitive
concerns, older than 60
MEG and T1 MRI Cross-sectional NC: n = 39 (70.4 ± 3.7)
SCD: n = 41 (71.6 ± 4.5)
MCI: n = 51 (73 ± 3.7)
SCD and MCI exhibited a similar
reduction in alpha band activity
compared with NC. MCI showed
a slowing in alpha peak frequency
compared with both SCD and NC.
Lopez-Sanz et al. (2017) [168] Self-reported cognitive
concerns, older than 60
MEG and T1 MRI Cross-sectional NC: n = 39 (70.4 ± 3.7)
SCD: n = 41 (71.6 ± 4.5)
MCI: n = 51 (73 ± 3.7)
SCD and MCI showed lower FC in
a hyper-synchronized anterior
network and a posterior network.
Lopez-Sanz et al. (2017) [168] Self-reported cognitive
concerns, older than 60
MEG and T1 MRI Cross-sectional NC: n = 63 (70.7 ± 4.5)
SCD: n = 55 (71.0 ± 5.0)
MCI: n = 69 (71.9 ± 4.2)
SCD showed decreased clustering
and transitivity in theta and beta
bands but increased modularity
and transitivity in alpha band.
Maestu et al. (2011) [176] Patient stating that their
memory function has
deteriorated compared
to earlier stages in life
MEG Cross-sectional NC: n = 6 (72 ± 8)
SCD: n = 12 (72 ± 6)
MCI: n = 21 (75 ± 3)
The SCD showed higher activation
than the control group in posterior
ventral regions and in the dorsal
pathway. MCI patients showed
higher activation than the control
group in the posterior part of the
ventral pathway.
Prichep et al., (2006) [174] Memory clinic consultation EEG Cross-sectional Nondecliners: n = 17
(70.0 ± 4.1)
Decliners: n =27 (73.5 ± 4.9)
Decliners showed increase in
theta power.
SCD Subjective cognitive decline, AD Alzheimer’s disease, MCI Mild cognitive impairment, aMCI Amnestic MCI, naMCI Non-amnestic MCI, NC Normal control, PET
Positron emission tomography, MRI Magnetic resonance imaging, EEG Electroencephalography, MEG Magnetoencephalography, SCD-I Subjective Cognitive Decline
Initiative, FC Functional connectivity
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SCD with the AD-like pattern, as an appropriate risk
population [183]. More comprehensively, Wirth et al. in-
corporated amyloid PET, FDG-PET and structural MRI
data to determine the pathological pattern in the AD
continuum. The results revealed three distinct imaging
biomarker patterns, which were detected in individuals
with different stages of AD [184].
Regarding the relationship between amyloid and func-
tional alterations, several studies have presented diverse
results. Chiesa et al. described an association between a
greater amyloid load and reduced posterior basal fore-
brain resting-state functional connectivity (RSFC) in the
hippocampus and thalamus [185]. Li et al. showed a
positive association between a higher degree centrality
[186] of the bilateral hippocampus and left fusiform
gyrus with total tau and phosphorylated tau levels, rather
than cerebral amyloid deposition [187]. Additional stud-
ies have reported significantly decreased WM connec-
tions and FC loss in individuals with SCD [113]. Thus,
the relationship between AD pathology and brain func-
tion during the SCD stage lacks accurate evidence,
which may be due to the different methodologies used
to acquire parameters, preprocess data and quantify the
results.
Multimodal studies involving EEG have indicated
that the slowing property detected with EEG was re-
lated to white matter lesions (WMLs) and medial
temporal atrophy (MTA), but not to the amyloid load
[178, 188]. Gaubert et al. divided patients with SCD
into four subgroups according to their amyloid status
(based on 18F-florbetapir PET) and neurodegeneration
status (based on FDG-PET). The results demonstrated
that in neurodegeneration-positive subjects, amyloid
burden was related to delta power following a U-
shaped curve and related to other EEG metrics, such
as gamma power, spectral entropy, and complexity,
following an inverted U-shaped curve [189].
Tau protein deposition is regarded as another critical
pathological biomarker of AD. However, the complicated
relationships between amyloid, tau, neurodegenerations
and cognitive decline are not clearly understood. Studies
using amyloid PET and tau PET have coincidentally sug-
gested that both tau protein and amyloid pathology con-
tributed to the manifestation of SCD [190, 191].
Specifically, amyloid and tau pathologies may give rise to
different subjective cognitive domains [191].
In longitudinal studies using FDG-PET and MRI mo-
dalities, the longitudinal reduction in cognitive perform-
ance was associated with brain hypometabolism in the
precuneus at baseline, but not with gray matter atrophy
[59]. Specifically, patients with SCD from the clinic dis-
played greater gray matter atrophy progression over time
compared with patients with SCD from the community,
indicating that clinical SCD may represent a greater risk
of dementia due to AD [192]. Overall, the multimodal
neuroimaging technique offers a great advantage in ex-
ploring the relationship between different AD bio-
markers, and more multimodal neuroimaging studies of
SCD are required (Table 5).
Shortcomings and emerging trends
Factors contributing to heterogeneous neuroimaging
findings in SCD
The inconsistent and heterogeneous neuroimaging find-
ings in SCD may result from several factors: (a) The use
of different diagnostic criteria and assessment strategies
for SCD may be a factor contributing to the
heterogenous findings. Although unified research criteria
for SCD have been proposed by SCD-I, it has not been
universally used. The evaluation and classification mea-
surements of SCD vary among investigations, including
both qualitative methods (SCD/no SCD based on binary
questions) and quantitative measures (e.g., E-Cog, MFQ,
and Memory Assessment Clinics Questionnaire (MAC-
Q)) (b) Variations in the demographics of the cohorts,
both within and across studies, may be another influen-
cing factor. Converging evidence has suggested that
demographic characteristics such as age, sex, education
level and the presence of the ApoE ɛ4 allele are import-
ant factors influencing cognition. However, the distribu-
tions of these demographics are highly variable. (c)
Methodological differences in the acquisition of parame-
ters and the quantification methods (e.g., voxel-based
analysis, region-of-interest analysis, connectivity or
connectome-based approaches) may also be factors pro-
ducing some inconsistencies in the results, indicating
that the interpretations and comparisons of these find-
ings should be viewed with caution. However, despite
the existence of these influencing factors, most studies
included in the current review still described some com-
mon neuroimaging alterations in individuals with SCD.
Longitudinal imaging studies
Longitudinal research in this field is still limited. Most of
the studies investigating the neuroimaging changes in in-
dividuals with SCD often employ a cross-sectional design
in which neuroimaging measures are compared between
individuals with SCD and HCs. However, this commonly
used design does not account for the differences in indi-
vidual trajectories of brain changes. Longitudinal studies
including follow-up scans enable the assessment of indi-
vidual trajectories of brain changes and the identification
of AD pathology in subjects with SCD. Additionally, longi-
tudinal studies facilitate the investigation and validation of
causality between pathological markers and emerging neu-
rodegeneration and cognitive decline. Importantly, longi-
tudinal designs allow researchers to explore biomarkers
for the early prediction of disease conversion by
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Table 5 Summary of multimodal studies
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
Buckley et al.
(2017) [190]
SCD composite
questions
PiB-PET
FTP-PET
Cross-sectional All: n = 133 (75.9±7.0)
Aß negative: n = 94
(74.9±7.2)
Aß positive: n = 39
(78.4±5.7)
Greater SCD relate to increased
entorhinal tau burden and Aß
burden
Chetelat et al.
(2010) [180, 181]
1 binary question PiB-PET
MRI
Cross-sectional NC: n = 45 (74.9±7.1)
SCI: n = 49 (73.9±7.2)
MCI:n = 34 (75.4±7.2)
AD: n = 35 (75.1±7.9)
Relation between global and
regional atrophy and Aβ-amyloid
load in SCI individuals but not in
MCI or AD dementia
Ché telat et al.
(2010) [180, 181]
1 binary question PiB-PET
MRI
Cross-sectional HC-: n = 32 (73.1±7.1)
HC+: n = 13 (78.9±5.5)
SCI-: n = 30 (72.1±7.1)
SCI+: n = 19 (76.7±6.5)
MCI+: n = 22 (75.8±7.1)
AD+: n = 34 (75±7.9)
Larger temporal gray matter
volume in HC with high amyloid
load; gray matter atrophy in SCI
with high amyloid load and MCI
compared to HC
Chiesa et al.
(2019) [140, 185]
2 binary questions 18F-florbetapir
PET
Rs-fMRI
Cross-sectional Overall: n = 267 (75.8±3.5)
ApoE ɛ4 noncarriers:
n = 192 (75.7±3.6)
ApoE ɛ4 carriers:
n = 53 (76.1±3.6)
Higher SUVR values related to
lower posterior basal forebrain
RSFC in the hippocampus and
the thalamus, impacted by sex
and ApoE genotype
Chiesa et al.
(2019) [140, 185]
2 binary questions 18F-florbetapir
PET
Rs-fMRI
Cross-sectional All: n = 224 (75.5±3.4)
ApoE ɛ4 noncarriers:
n = 180 (75.5±3.4)
ApoE ɛ4 carriers:
n = 44 (75.6±3.5)
DMN changes in frontal and
posterior areas and right
hippocampus. No impact
of brain amyloid load status
on longitudinal RSFC.
Eliassen et al.
(2017) [193]
Cognitive complaints FDG-PET
MRI
Cross-sectional aMCI: n = 53(61.9±7.8)
naMCI: n = 27(60.7±7.8)
SCD: n = 38(59±8.3)
Lower cortical glucose
metabolism in aMCI than
SCD and controls. Thinner
entorhinal cortex in SCD
and aMCI
Ferreira et al.
(2017) [183]
1 binary question PiB-PET
MRI
Cross-sectional HC-like SMD: n = 75
(72.5±6.8)
AD-like SMD: n = 11
(75.3±8.8)
The disease severity index
identified eleven (13%) SCD
with AD-like pattern of brain
atrophy, who show lower
cognitive performance, higher
amyloid deposition, and worse
clinical progression
Gaubert et al.
(2019) [189]
Memory complaint 18F-florbetapir
PET
EEG
Cross-sectional All: n = 314 (76.07±3.47)
A-N-: n = 175 (75.62±3.39)
A+N-: n = 63 (76.81±3.19)
A+N+: n = 25 (76.88±4.01)
EEG metrics of fronto-central
regions correlate with
neurodegeneration. A U-shape
or inverted U-shape relationships
between amyloid burden and
EEG metrics in neurodegeneration
positive subjects
Kramberger et al.
(2017) [188]
Memory clinic
consultation
EEG
MRI
Cross-sectional SCI: n = 194 (57.7±7.5)
MCI: n = 141 (61.7±8.3)
AD: n = 58 (63.6±7.0)
WMLs and medial temporal
atrophy relate to slower BA
in all diagnoses
Kuhn et al.
(2019) [192]
Composite of
10 questions
CDS
18F-florbetapir
PET
FDG-PET
MRI
Longitudinal
(15-43 months)
HC: n=28 (72.25±6.33)
SCD-community: n = 23
(71.70±6.60)
SCD-clinic:
n = 27 (68.30±7,99)
Higher self-reported SCD
relate to lower gray matter
volume and higher anxiety in
SCD-community, to greater i
nformant-reported SCD in
SCD-clinic and to lower glucose
metabolism in both SCD groups
Li et al. (2018) [187] CCI 18F-florbetapir
PET
MRI
Cross-sectional NC: n = 40 (75.10±5.39)
SMC: n = 44 (73.78±5.81)
Higher DC in the bilateral
hippocampus and left fusiform
gyrus and lower DC in inferior
parietal in SMC. DC in bilateral
hippocampus and left fusiform
relate to total tau and
phosphorylated tau, but not
to amyloid deposition
Scheef et al.
(2012) [59]
Memory clinic
consultation
2 binary
questions
FDG-PET
MRI
Cross-sectional Controls: n = 56 (66.4±7.2)
SMI: n = 31 (67.6±6.2)
Hypometabolism in right
precuneus and hypermetabolism
in right medial temporal and
reduced gray matter volume in
hippocampus in SMI group.
Longitudinal memory decline
relates to reduced glucose
metabolism in right precuneus
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investigating the subsets of patients with SCD who ultim-
ately progress to dementia due to AD.
It is encouraging to learn that multiple international
neuroimaging projects investigating dementia due to AD
or preclinical AD are collecting data via longitudinal de-
signs. Specifically, the ADNI database, an integral part of
a multisite longitudinal study, is collecting multimodal
imaging data (including MRI, DTI, fMRI and PET) and
has started adding an SCD group from ADNI-2 [194].
MEMENTO is a clinic-based study that recruited 2323
patients with cognitive impairments and subjects with
SCD at baseline who will be followed over a 5-year
period [195]. In addition, the FACEHBI [196], INSI
GHT-preAD [197], DELCODE [198] and SILCODE
(trial registration: NCT03370744) [199] are ongoing lon-
gitudinal observational studies of individuals with SCD
that will facilitate research exploring the developmental
trajectory of different pathological biomarkers in AD.
Importantly, opening and sharing these neuroimaging
datasets of patients with SCD has been encouraged to
accelerate the development of research in this field.
Multimodal imaging studies
Different neuroimaging techniques have captured differ-
ent aspects of the brain abnormalities involved in SCD
to help reveal its multimodal signature. However, no
single-modality imaging method is currently able to ac-
curately characterize the pathological mechanisms
underlying the full spectrum of SCD. Thus, the increas-
ingly utility of multimodal neuroimaging technology
provides an opportunity to determine the complicated
relationships between amyloid, tau and downstream
neurodegenerative pathologies occurring in the AD
process. For SCD populations, several studies combining
multimodal neuroimaging techniques such as PET and
MRI have recently been conducted. However, the
Table 5 Summary of multimodal studies (Continued)
Authors Definition of SCD Modality Design Sample (mean age ± SD) Main findings
in SMI
Shokouhi et al.
(2019) [191]
E-Cog 18F-flortaucipir PET
18F-florbetapir PET
Cross-sectional All: n = 86 (78±8) Tau pathology predict everyday
planning in SCD, and amyloid
pathology relate to everyday
organization and memory in
SCD
Teipel et al.
(2018) [178]
2 binary questions 18F-florbetapir
PET
MRI
EEG
Cross-sectional Amyloid negative: n = 63
(75.9±3.5)
Amyloid positive: n = 255
(76.7±3.5)
No significant relationship
between amyloid load and
phase-lag index in any
frequency band
Teipel et al.
(2017) [182]
2 binary questions 18F-florbetapir
PET
MRI
Cross-sectional All: n = 318 (76.1±3.5) Association between amyloid
uptake and reduced gray
matter structural integrity
and poorer objective cognitive
performance
Ten Kate et al.
(2018) [101]
2 binary questions 18F-florbetapir
PET
MRI
Cross-sectional All: n=318(76 74±78)
Amyloid-:
n = 230 (76 73±78)
Amyloid+:
n = 88 (77 75±79)
Association between higher
global SUVR and lower clustering,
and small world values in orbito-
and dorsolateral frontal and
parietooccipital regions.
Wirth et al.
(2018) [184]
Memory clinic
consultation
18F-florbetapir
PET
MRI
FDG-PET
Cross-sectional HC: n=41 (66.1 ±7.7)
ApoE ɛ4+: n = 17
(63.9±8.6)
SCD: n=16 (68.9±7.3)
MCI: n=30 (73.4±7.2)
AD: n=22 (68.7±9.4)
(1) in medial-temporal regions,
local gray matter volume
reduction exceeded
hypometabolism, (2) in
temporoparietal regions,
hypometabolism predominated
over gray matter volume reduction,
and (3) in frontal regions, Aβ
deposition exceeded gray matter
volume reduction and hypometabolism.
Three distinct biomarker patterns in
MCI, only pattern 1 in SCD, only
pattern 3 in ApoE ɛ4 carriers
Yasuno et al.
(2015) [113]
EMC PiB-PET
MRI
Cross-sectional nSCI: n = 30 (72.2±4.8)
SCI: n = 23 (69.6±8.0)
Reduced FC in cortical midline
structure in SCI. reduced WM
connections relate to reduced FC.
No amyloid deposition in SCI
SCC Subjective cognitive complaints, ND Neurodegeneration, FDG 18F-Fluorodeoxyglucose, EEG Electroencephalography, WM White matter, SMD Subjective
memory decline, FTP Flortaucipir, SCD Subjective cognitive decline, CDR Clinical dementia rating, E-Cog Everyday Cognition Scale, AD Alzheimer’s disease, SMI
Subjective memory impairment, CMRglc Cerebral metabolic rates for glucose, ApoE Apolipoprotein E, FCSRT Free and cued selective reminding test, BNT Boston
naming test, VOSP Visual object and space perception battery, ToL Tower of London test, IP Isoprostane, SUVR Standardized uptake value ratio, SCI Subjective
cognitive impairment, MCI Mild cognitive impairment, aMCI Amnestic MCI, naMCI Non-amnestic MCI, NC Normal control, PET Positron emission tomography, PiB
Pittsburgh compound B. ADNI: Alzheimer’s Disease Neuroimaging Initiative, MRI Magnetic resonance imaging, WMLs White matter lesions, rs-fMRI Resting-state
functional MRI, DMN Default mode network, RSFC Resting-state functional connectivity, FC Functional connectivity, DC Degree centrality
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complicated relationships between distinct pathological
biomarkers, such as amyloid, tau, and macroscale struc-
tural and functional brain alterations during the SCD
stage, from local to connectivity level changes, still re-
main largely unexplored. More multimodal imaging
studies are urgently needed to understand the interac-
tions between different pathological changes in the early
stage of AD.
Additionally, newly developed molecular tracers, im-
aging sequences and ultrahigh field MRI techniques, such
as the use of 7-T scanners, will be helpful to detect more
subtle alterations in the early stage of the disease and
should be applied to further investigate SCD populations.
Individual prediction with artificial intelligence
Artificial intelligence, such as machine learning and deep
learning, offers a systematic approach to developing so-
phisticated, automatic, and objective classification frame-
works for analyzing high-dimensional data. Additionally,
artificial intelligence techniques are able to learn complex
and subtle patterns of change across various imaging mo-
dalities [200]. Over the last decade, classification methods
based on imaging have been increasingly integrated to
identify the imaging signature of AD [201–203], offering
promising tools for individualized diagnoses and prognos-
tic predictions. However, until recently, neuroimaging-
based studies for classifying SCD have been scarce [111,
126, 135, 204–206]. The early identification of SCD and
the prediction of disease progression at the individual level
is important for timely interventions. Furthermore, ma-
chine learning not only detects subtle and distributed
changes but also enables the extraction of biomarkers
from high-dimensional neuroimaging data. Recently, the
neuroimaging-based “brain age” has been proposed as an
important biomarker of an individual’s brain health [207].
Additionally, the SPARE-AD index was proposed based
on a support vector machine (SVM) classifier between
HCs and age-matched patients with dementia due to AD
and was used to quantify the spatial pattern of abnormal-
ity [201]. Peter and colleagues used similar methods and
showed that the extracted index was higher in individuals
with SCD than in HCs [95]. The biomarker obtained
based on machine learning might be more sensitive at de-
tecting the early stage of AD because it captures a multi-
variable pattern. Overall, artificial intelligence combined
with neuroimaging big data has the potential to enable in-
dividualized diagnoses of SCD due to AD and to extract
sensitive imaging biomarkers from important features se-
lected from high-dimensional neuroimaging data.
Conclusions
In this review, we have provided a comprehensive sum-
mary of the molecular, structural and functional brain
alterations of individuals with SCD related to AD
Fig. 2 Multimodal imaging signature of SCD. The consistent results were collected from the articles included in this review to provide a
comprehensive summary of common neuroimaging changes in SCD. a SCD individuals exhibit a pattern of amyloid accumulation within the
medial prefrontal, cingulum and precuneus cortex, which are early sites of vulnerability in MCI and dementia due to AD. b The medial temporal
lobe is frequently characterized by hypometabolism, whereas other studies have reported a strong association between SCD and
hypometabolism within the precuneus. c Individuals with SCD showed decreased hippocampal volume and thinner entorhinal cortex than
healthy controls. d The abnormal FC between the posterior DMN and other regions are frequently reported in resting-state fMRI studies. e DTI
studies have reported decreased FA in hippocampal and parahippocampal white matter in SCD individuals. Abbreviations: SCD = Subjective
cognitive decline; MCI = Mild cognitive impairment; AD = Alzheimer’s disease; DTI = Diffusion tensor imaging; DMN = Default mode network;
fMRI = Functional MRI; FC=Functional connectivity
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investigated at different scales, ranging from regional to
large-scale network-based imaging measures.
We collected consistent results from the articles in-
cluded in this review and summarized the shared neuro-
imaging changes observed in individuals with SCD in
the context of AD, as shown in Fig. 2. Regarding the
pathological alterations at the molecular level, PET stud-
ies have observed early amyloid deposition, an increased
tau burden and hypometabolism in individuals with
SCD. MRI techniques enable assessments of alterations
in macroscopic brain structures, such as decreased hip-
pocampal volume and thinner entorhinal cortex; as well
as microstructural deficits in WM tracts, such as de-
creased FA in the hippocampus and parahippocampal
gyrus and abnormal functional activity. These assess-
ments also illustrate the abnormal FC of the DMN and
topological alterations in the whole-brain connectome.
Based on these findings, we identify a preferential vul-
nerability of highly selected brain regions that are mainly
affected in individuals with MCI or dementia due to AD,
including the hippocampus, medial temporal lobe, pre-
cuneus and temporoparietal regions, indicating that indi-
viduals with SCD share a similar pattern of pathological
alterations with individuals with MCI and dementia due
to AD. As different neuroimaging techniques can reflect
different aspects of brain abnormalities, we also suggest
that the combination of multiple imaging modalities
may provide a more comprehensive understanding of
the pathological process than a single modality. How-
ever, a small number of conflicting findings of neuroim-
aging changes in individuals with SCD due to AD exist,
including reports of no relationship between SCD and
amyloid pathology, the preservation of gray matter struc-
ture (e.g., the hippocampal volume) and WM integrity,
and even hypermetabolism of cerebral glucose in SCD
subjects. In particular for studies of brain function, al-
though most studies have reported abnormal FC of the
DMN in individuals with SCD, the directions of these
results (i.e., increased FC or reduced FC) are still rela-
tively inconsistent. These inconsistent results may be
due to the differences in the methods used to classify
and assess SCD, the demographics of the cohorts, and
the acquisition of parameters and quantification
methods.
In conclusion, the pathological alterations underlying
the manifestation of SCD are parallel to those underlying
MCI and dementia due to AD based on the results ob-
tained using neuroimaging techniques, supporting the
notion that SCD represents an early precursor of de-
mentia due to AD. While cognitive function is pre-
served, early detection of SCD is imperative to ensure
that patients will benefit from early intervention and ob-
tain the appropriate treatment in a timely manner. In
the future, with additional validation studies of larger
samples and longitudinal studies, the combination of
multimodal neuroimaging techniques may help identify
SCD individuals presenting with early AD pathologies
who may be eligible for clinical trials for the early detec-
tion and secondary intervention of AD.
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